- Home
- RSVR vs ITOS Comparison
RSVR vs ITOS Comparison
Compare RSVR & ITOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RSVR
- ITOS
- Stock Information
- Founded
- RSVR 2007
- ITOS 2011
- Country
- RSVR United States
- ITOS United States
- Employees
- RSVR N/A
- ITOS N/A
- Industry
- RSVR Movies/Entertainment
- ITOS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RSVR Consumer Discretionary
- ITOS Health Care
- Exchange
- RSVR Nasdaq
- ITOS Nasdaq
- Market Cap
- RSVR 504.1M
- ITOS 446.6M
- IPO Year
- RSVR N/A
- ITOS 2020
- Fundamental
- Price
- RSVR $8.06
- ITOS $10.19
- Analyst Decision
- RSVR Strong Buy
- ITOS Hold
- Analyst Count
- RSVR 1
- ITOS 6
- Target Price
- RSVR $11.50
- ITOS $10.40
- AVG Volume (30 Days)
- RSVR 65.7K
- ITOS 1.0M
- Earning Date
- RSVR 08-05-2025
- ITOS 08-06-2025
- Dividend Yield
- RSVR N/A
- ITOS N/A
- EPS Growth
- RSVR N/A
- ITOS N/A
- EPS
- RSVR 0.12
- ITOS N/A
- Revenue
- RSVR $161,553,186.00
- ITOS N/A
- Revenue This Year
- RSVR $7.04
- ITOS N/A
- Revenue Next Year
- RSVR $6.23
- ITOS N/A
- P/E Ratio
- RSVR $68.89
- ITOS N/A
- Revenue Growth
- RSVR 9.65
- ITOS 177.89
- 52 Week Low
- RSVR $6.56
- ITOS $4.80
- 52 Week High
- RSVR $9.83
- ITOS $18.01
- Technical
- Relative Strength Index (RSI)
- RSVR 59.99
- ITOS 60.66
- Support Level
- RSVR $7.62
- ITOS $10.10
- Resistance Level
- RSVR $7.97
- ITOS $10.22
- Average True Range (ATR)
- RSVR 0.24
- ITOS 0.04
- MACD
- RSVR 0.02
- ITOS -0.00
- Stochastic Oscillator
- RSVR 95.49
- ITOS 78.57
About RSVR Reservoir Media Inc.
Reservoir Media Inc is an independent music company. It operates a music publishing business, a recorded music business, a management business, and a rights management entity in the Middle East. The company's segments include Music Publishing and Recorded Music. It generates the maximum of its revenue from the Music Publishing segment.
About ITOS iTeos Therapeutics Inc.
ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.